APO Research
Talk to an analyst

APO RESEARCH · REPORT

Relapsed Acute Myeloid Leukemia Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Relapsed Acute Myeloid Leukemia Drug Market Outlook and Growth Opportunities 2026

19 December 2025200 pages

Choose your research edition.

Industry ResearchRelapsed Acute Myeloid Leukemia Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Relapsed Acute Myeloid Leukemia Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Relapsed Acute Myeloid Leukemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Relapsed Acute Myeloid Leukemia Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Relapsed Acute Myeloid Leukemia Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Relapsed Acute Myeloid Leukemia Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Relapsed Acute Myeloid Leukemia Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Relapsed Acute Myeloid Leukemia Drug market include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Relapsed Acute Myeloid Leukemia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Relapsed Acute Myeloid Leukemia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Relapsed Acute Myeloid Leukemia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Relapsed Acute Myeloid Leukemia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Relapsed Acute Myeloid Leukemia Drug Segment by Company

4SC AG

Amgen Inc.

AbbVie Inc.

AstraZeneca Plc

CTI BioPharma Corp.

Cornerstone Pharmaceuticals, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

Bristol-Myers Squibb Company

Boston Biomedical, Inc.

Boehringer Ingelheim GmbH

BioLineRx, Ltd.

AVEO Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc.

Astellas Pharma Inc.

Array BioPharma Inc.

Arog Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Relapsed Acute Myeloid Leukemia Drug Segment by Type

aNK Program

AT-9283

BI-836858

BL-8040

Binimetinib

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Application

Clinic

Hospital

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Relapsed Acute Myeloid Leukemia Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Relapsed Acute Myeloid Leukemia Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Relapsed Acute Myeloid Leukemia Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Relapsed Acute Myeloid Leukemia Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Relapsed Acute Myeloid Leukemia Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Relapsed Acute Myeloid Leukemia Drug industry.

Chapter 3: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Relapsed Acute Myeloid Leukemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Relapsed Acute Myeloid Leukemia Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Relapsed Acute Myeloid Leukemia Drug Industry Trends Table 2. Relapsed Acute Myeloid Leukemia Drug Industry Drivers Table 3. Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges Table 4. Relapsed Acute Myeloid Leukemia Drug Industry Restraints Table 5. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Company (2021-2026) Table 7. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Company (2021-2026) Table 9. Global Relapsed Acute Myeloid Leukemia Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Relapsed Acute Myeloid Leukemia Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Relapsed Acute Myeloid Leukemia Drug Key Company Manufacturing Base & Headquarters Table 12. Global Relapsed Acute Myeloid Leukemia Drug Company, Product Type & Application Table 13. Global Relapsed Acute Myeloid Leukemia Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of aNK Program Table 18. Significant Companies of AT-9283 Table 19. Significant Companies of BI-836858 Table 20. Significant Companies of BL-8040 Table 21. Significant Companies of Binimetinib Table 22. Significant Companies of Others Table 23. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Type (2021-2026) Table 27. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Type (2027-2032) Table 28. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type (2021-2026) Table 32. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Others Table 36. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Application (2021-2026) Table 40. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Application (2027-2032) Table 41. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application (2021-2026) Table 45. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application (2027-2032) Table 46. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2021-2026) Table 49. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2027-2032) Table 51. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Region (2021-2026) Table 54. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Region (2027-2032) Table 56. Global Relapsed Acute Myeloid Leukemia Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Relapsed Acute Myeloid Leukemia Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 61. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2026) Table 62. Global Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2027-2032) Table 64. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Market Share by Country (2027-2032) Table 68. 4SC AG Company Information Table 69. 4SC AG Business Overview Table 70. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 72. 4SC AG Recent Development Table 73. Amgen Inc. Company Information Table 74. Amgen Inc. Business Overview Table 75. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 77. Amgen Inc. Recent Development Table 78. AbbVie Inc. Company Information Table 79. AbbVie Inc. Business Overview Table 80. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 82. AbbVie Inc. Recent Development Table 83. AstraZeneca Plc Company Information Table 84. AstraZeneca Plc Business Overview Table 85. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 87. AstraZeneca Plc Recent Development Table 88. CTI BioPharma Corp. Company Information Table 89. CTI BioPharma Corp. Business Overview Table 90. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 92. CTI BioPharma Corp. Recent Development Table 93. Cornerstone Pharmaceuticals, Inc. Company Information Table 94. Cornerstone Pharmaceuticals, Inc. Business Overview Table 95. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 97. Cornerstone Pharmaceuticals, Inc. Recent Development Table 98. Celgene Corporation Company Information Table 99. Celgene Corporation Business Overview Table 100. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 102. Celgene Corporation Recent Development Table 103. Calithera Biosciences, Inc. Company Information Table 104. Calithera Biosciences, Inc. Business Overview Table 105. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 107. Calithera Biosciences, Inc. Recent Development Table 108. Bristol-Myers Squibb Company Company Information Table 109. Bristol-Myers Squibb Company Business Overview Table 110. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 112. Bristol-Myers Squibb Company Recent Development Table 113. Boston Biomedical, Inc. Company Information Table 114. Boston Biomedical, Inc. Business Overview Table 115. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 117. Boston Biomedical, Inc. Recent Development Table 118. Boehringer Ingelheim GmbH Company Information Table 119. Boehringer Ingelheim GmbH Business Overview Table 120. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 122. Boehringer Ingelheim GmbH Recent Development Table 123. BioLineRx, Ltd. Company Information Table 124. BioLineRx, Ltd. Business Overview Table 125. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 127. BioLineRx, Ltd. Recent Development Table 128. AVEO Pharmaceuticals, Inc. Company Information Table 129. AVEO Pharmaceuticals, Inc. Business Overview Table 130. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 132. AVEO Pharmaceuticals, Inc. Recent Development Table 133. Astex Pharmaceuticals, Inc. Company Information Table 134. Astex Pharmaceuticals, Inc. Business Overview Table 135. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 137. Astex Pharmaceuticals, Inc. Recent Development Table 138. Astellas Pharma Inc. Company Information Table 139. Astellas Pharma Inc. Business Overview Table 140. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 142. Astellas Pharma Inc. Recent Development Table 143. Array BioPharma Inc. Company Information Table 144. Array BioPharma Inc. Business Overview Table 145. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 147. Array BioPharma Inc. Recent Development Table 148. Arog Pharmaceuticals, Inc. Company Information Table 149. Arog Pharmaceuticals, Inc. Business Overview Table 150. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 152. Arog Pharmaceuticals, Inc. Recent Development Table 153. Agios Pharmaceuticals, Inc. Company Information Table 154. Agios Pharmaceuticals, Inc. Business Overview Table 155. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 157. Agios Pharmaceuticals, Inc. Recent Development Table 158. Actinium Pharmaceuticals, Inc. Company Information Table 159. Actinium Pharmaceuticals, Inc. Business Overview Table 160. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 162. Actinium Pharmaceuticals, Inc. Recent Development Table 163. Key Raw Materials Table 164. Raw Materials Key Suppliers Table 165. Relapsed Acute Myeloid Leukemia Drug Distributors List Table 166. Relapsed Acute Myeloid Leukemia Drug Customers List Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Relapsed Acute Myeloid Leukemia Drug Product Image Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Relapsed Acute Myeloid Leukemia Drug Sales (2021-2032) & (K Units) Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. aNK Program Image Figure 10. AT-9283 Image Figure 11. BI-836858 Image Figure 12. BL-8040 Image Figure 13. Binimetinib Image Figure 14. Others Image Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application (2021-2032) Figure 30. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Relapsed Acute Myeloid Leukemia Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Relapsed Acute Myeloid Leukemia Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • aNK Program
  • AT-9283
  • BI-836858
  • BL-8040
  • Binimetinib
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • 4SC AG
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • CTI BioPharma Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Boehringer Ingelheim GmbH
  • BioLineRx, Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Astex Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Array BioPharma Inc.
  • Arog Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032)
  4. 1.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Relapsed Acute Myeloid Leukemia Drug Market Dynamics
  1. 2.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
  2. 2.2 Relapsed Acute Myeloid Leukemia Drug Industry Drivers
  3. 2.3 Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges
  4. 2.4 Relapsed Acute Myeloid Leukemia Drug Industry Restraints
3 Relapsed Acute Myeloid Leukemia Drug Market by Company
  1. 3.1 Global Relapsed Acute Myeloid Leukemia Drug Company Revenue Ranking in 2025
  2. 3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2021-2026)
  3. 3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Company (2021-2026)
  5. 3.5 Global Relapsed Acute Myeloid Leukemia Drug Company Ranking (2024-2026)
  6. 3.6 Global Relapsed Acute Myeloid Leukemia Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Relapsed Acute Myeloid Leukemia Drug Company Product Type and Application
  8. 3.8 Global Relapsed Acute Myeloid Leukemia Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Relapsed Acute Myeloid Leukemia Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Relapsed Acute Myeloid Leukemia Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Relapsed Acute Myeloid Leukemia Drug Market by Type
  1. 4.1 Relapsed Acute Myeloid Leukemia Drug Type Introduction
  2. 4.1.1 aNK Program
  3. 4.1.2 AT-9283
  4. 4.1.3 BI-836858
  5. 4.1.4 BL-8040
  6. 4.1.5 Binimetinib
  7. 4.1.6 Others
  8. 4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type
  9. 4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type
  13. 4.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type (2021-2032)
5 Relapsed Acute Myeloid Leukemia Drug Market by Application
  1. 5.1 Relapsed Acute Myeloid Leukemia Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application
  6. 5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application
  10. 5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application (2021-2032)
6 Relapsed Acute Myeloid Leukemia Drug Regional Sales and Value Analysis
  1. 6.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032)
  5. 6.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Relapsed Acute Myeloid Leukemia Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032)
  12. 6.6.2 North America Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032)
  21. 6.9.2 South America Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Country, 2025 VS 2032
7 Relapsed Acute Myeloid Leukemia Drug Country-level Sales and Value Analysis
  1. 7.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032)
  6. 7.4 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Relapsed Acute Myeloid Leukemia Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Relapsed Acute Myeloid Leukemia Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 4SC AG
  2. 8.1.1 4SC AG Company Information
  3. 8.1.2 4SC AG Business Overview
  4. 8.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  6. 8.1.5 4SC AG Recent Developments
  7. 8.2 Amgen Inc.
  8. 8.2.1 Amgen Inc. Company Information
  9. 8.2.2 Amgen Inc. Business Overview
  10. 8.2.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  12. 8.2.5 Amgen Inc. Recent Developments
  13. 8.3 AbbVie Inc.
  14. 8.3.1 AbbVie Inc. Company Information
  15. 8.3.2 AbbVie Inc. Business Overview
  16. 8.3.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  18. 8.3.5 AbbVie Inc. Recent Developments
  19. 8.4 AstraZeneca Plc
  20. 8.4.1 AstraZeneca Plc Company Information
  21. 8.4.2 AstraZeneca Plc Business Overview
  22. 8.4.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  24. 8.4.5 AstraZeneca Plc Recent Developments
  25. 8.5 CTI BioPharma Corp.
  26. 8.5.1 CTI BioPharma Corp. Company Information
  27. 8.5.2 CTI BioPharma Corp. Business Overview
  28. 8.5.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  30. 8.5.5 CTI BioPharma Corp. Recent Developments
  31. 8.6 Cornerstone Pharmaceuticals, Inc.
  32. 8.6.1 Cornerstone Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Cornerstone Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  36. 8.6.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Celgene Corporation
  38. 8.7.1 Celgene Corporation Company Information
  39. 8.7.2 Celgene Corporation Business Overview
  40. 8.7.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  42. 8.7.5 Celgene Corporation Recent Developments
  43. 8.8 Calithera Biosciences, Inc.
  44. 8.8.1 Calithera Biosciences, Inc. Company Information
  45. 8.8.2 Calithera Biosciences, Inc. Business Overview
  46. 8.8.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  48. 8.8.5 Calithera Biosciences, Inc. Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Boston Biomedical, Inc.
  56. 8.10.1 Boston Biomedical, Inc. Company Information
  57. 8.10.2 Boston Biomedical, Inc. Business Overview
  58. 8.10.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  60. 8.10.5 Boston Biomedical, Inc. Recent Developments
  61. 8.11 Boehringer Ingelheim GmbH
  62. 8.11.1 Boehringer Ingelheim GmbH Company Information
  63. 8.11.2 Boehringer Ingelheim GmbH Business Overview
  64. 8.11.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  66. 8.11.5 Boehringer Ingelheim GmbH Recent Developments
  67. 8.12 BioLineRx, Ltd.
  68. 8.12.1 BioLineRx, Ltd. Company Information
  69. 8.12.2 BioLineRx, Ltd. Business Overview
  70. 8.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  72. 8.12.5 BioLineRx, Ltd. Recent Developments
  73. 8.13 AVEO Pharmaceuticals, Inc.
  74. 8.13.1 AVEO Pharmaceuticals, Inc. Company Information
  75. 8.13.2 AVEO Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  78. 8.13.5 AVEO Pharmaceuticals, Inc. Recent Developments
  79. 8.14 Astex Pharmaceuticals, Inc.
  80. 8.14.1 Astex Pharmaceuticals, Inc. Company Information
  81. 8.14.2 Astex Pharmaceuticals, Inc. Business Overview
  82. 8.14.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  84. 8.14.5 Astex Pharmaceuticals, Inc. Recent Developments
  85. 8.15 Astellas Pharma Inc.
  86. 8.15.1 Astellas Pharma Inc. Company Information
  87. 8.15.2 Astellas Pharma Inc. Business Overview
  88. 8.15.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  90. 8.15.5 Astellas Pharma Inc. Recent Developments
  91. 8.16 Array BioPharma Inc.
  92. 8.16.1 Array BioPharma Inc. Company Information
  93. 8.16.2 Array BioPharma Inc. Business Overview
  94. 8.16.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  96. 8.16.5 Array BioPharma Inc. Recent Developments
  97. 8.17 Arog Pharmaceuticals, Inc.
  98. 8.17.1 Arog Pharmaceuticals, Inc. Company Information
  99. 8.17.2 Arog Pharmaceuticals, Inc. Business Overview
  100. 8.17.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  102. 8.17.5 Arog Pharmaceuticals, Inc. Recent Developments
  103. 8.18 Agios Pharmaceuticals, Inc.
  104. 8.18.1 Agios Pharmaceuticals, Inc. Company Information
  105. 8.18.2 Agios Pharmaceuticals, Inc. Business Overview
  106. 8.18.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  108. 8.18.5 Agios Pharmaceuticals, Inc. Recent Developments
  109. 8.19 Actinium Pharmaceuticals, Inc.
  110. 8.19.1 Actinium Pharmaceuticals, Inc. Company Information
  111. 8.19.2 Actinium Pharmaceuticals, Inc. Business Overview
  112. 8.19.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  114. 8.19.5 Actinium Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
  2. 9.1.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Relapsed Acute Myeloid Leukemia Drug Sales Mode & Process
  6. 9.2 Relapsed Acute Myeloid Leukemia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Relapsed Acute Myeloid Leukemia Drug Distributors
  9. 9.2.3 Relapsed Acute Myeloid Leukemia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst